abrdn plc Trims Stock Holdings in Sanofi (NASDAQ:SNY)

abrdn plc lowered its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 30.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 250,085 shares of the company's stock after selling 109,348 shares during the quarter. abrdn plc's holdings in Sanofi were worth $14,412,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC raised its position in shares of Sanofi by 773.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,651 shares of the company's stock worth $275,000 after purchasing an additional 5,004 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Sanofi by 5.4% during the first quarter. Sequoia Financial Advisors LLC now owns 19,207 shares of the company's stock valued at $933,000 after acquiring an additional 978 shares during the last quarter. Mission Wealth Management LP lifted its position in shares of Sanofi by 24.3% in the first quarter. Mission Wealth Management LP now owns 5,185 shares of the company's stock valued at $252,000 after acquiring an additional 1,014 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Sanofi by 7.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,618 shares of the company's stock valued at $2,411,000 after acquiring an additional 3,268 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Sanofi by 35.4% in the first quarter. Blue Trust Inc. now owns 9,434 shares of the company's stock worth $458,000 after acquiring an additional 2,467 shares during the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Up 0.7 %

NASDAQ:SNY traded up $0.39 during trading hours on Friday, hitting $53.27. The company had a trading volume of 1,381,542 shares, compared to its average volume of 2,109,692. Sanofi has a 1 year low of $45.00 and a 1 year high of $58.97. The company has a market cap of $135.19 billion, a P/E ratio of 27.18, a P/E/G ratio of 1.35 and a beta of 0.61. The company has a 50-day moving average of $55.92 and a 200 day moving average of $52.00. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the prior year, the firm posted $2.55 earnings per share. Sanofi's quarterly revenue was up 12.3% on a year-over-year basis. Sell-side analysts expect that Sanofi will post 4.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on SNY shares. StockNews.com upgraded Sanofi from a "buy" rating to a "strong-buy" rating in a report on Wednesday. Citigroup raised shares of Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. Finally, Argus upped their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, July 26th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Sanofi currently has a consensus rating of "Buy" and a consensus target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.